Mutated protein of protein A having reduced affinity in acidic region and antibody-capturing agent

Patent metadata

Field	Value
Publication number	US-9382297-B2
Application number	US-201314095638-A
Country	US
Kind code	B2
Filing date	Dec 3, 2013
Priority date	Jun 3, 2011
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

A modified protein of an extracellular domain of protein A, which has the reduced ability to bind to immunoglobulin in an acidic region, compared with the wild-type extracellular domain of protein A, without impairing a selective antibody-binding activity in a neutral region. On the basis of three-dimensional structure coordinate data on a complex of the extracellular domain of protein A bound with the Fc region of immunoglobulin G, the modified protein is obtained by the substitution of amino acid residues that are located within the range of 10 angstroms from the Fc region and have a 20% or more ratio of exposed surface area, by histidine residues. Preferably, the modified protein is obtained by the substitution of amino acid residues at sites identified from the analysis of sequences selected from a library constituted by the protein group, by histidine residues. These substitutions may be combined.

First claim

The invention claimed is:

1. A mutant protein derived from the B domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 1, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO: 1 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 1; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type B domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 1 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

2. A mutant protein derived from the Z domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 2, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO: 2 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 2; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type Z domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 2 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

3. A mutant protein derived from the E domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 3, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO: 3 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 3; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type E domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 3 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

4. A mutant protein derived from the D domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 4, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO: 4 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 4; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type D domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 4 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

5. A mutant protein derived from the A domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 5, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO:5 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 5; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type A domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 5 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

6. A mutant protein derived from the C domain protein of protein A of the amino acid sequence set forth in SEQ ID NO: 6, the mutant protein having an amino acid sequence derived from the amino acid sequence set forth in SEQ ID NO:6 by the substitution of the amino acid residue of Asp36 by a histidine residue, the amino acid sequence having the same length as SEQ ID NO: 6; wherein the mutant protein has a binding activity to a constant region of immunoglobulin, and has a reduced binding activity to the constant region of immunoglobulin in an acidic region of the pH scale, compared with the wild-type C domain of protein A, and wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO:6 comprises the additional substitution of at least one of Gln9 and Gln10 by a histidine residue.

7. An immobilized protein comprising a protein according to any one of claims 1 to 6 immobilized on a water-insoluble solid-phase support.

8. A capturing agent for an antibody, immunoglobulin G, or a protein having a constant region of immunoglobulin, the capturing agent comprising an immobilized protein according to claim 7 .

9. The mutant protein of claim 1 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 1 includes the substitution of Gln9 by a histidine residue.

10. The mutant protein of claim 2 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 2 includes the substitution of Gln9 by a histidine residue.

11. The mutant protein of claim 3 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 3 includes the substitution of Gln9 by a histidine residue.

12. The mutant protein of claim 4 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 4 includes the substitution of Gln9 by a histidine residue.

13. The mutant protein of claim 5 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 5 includes the substitution of Gln9 by a histidine residue.

14. The mutant protein of claim 6 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 6 includes the substitution of Gln9 by a histidine residue.

15. The mutant protein of claim 1 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 1 includes the substitution of Gln10 by a histidine residue.

16. The mutant protein of claim 2 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 2 includes the substitution of Gln10 by a histidine residue.

17. The mutant protein of claim 3 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 3 includes the substitution of Gln10 by a histidine residue.

18. The mutant protein of claim 4 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 4 includes the substitution of Gln10 by a histidine residue.

19. The mutant protein of claim 5 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 5 includes the substitution of Gln10 by a histidine residue.

20. The mutant protein of claim 6 , wherein the amino acid derived from the amino acid sequence set forth in SEQ ID NO: 6 includes the substitution of Gln10 by a histidine residue.

Assignees

• Nat L Inst Of Advanced Ind Science And Technology
• Nat Inst Of Advanced Ind Scien

Inventors

• Honda Shinya
• Watanabe Hideki
• Tsukamoto Masayuki

Classifications

• C07K2319/705

  containing a protein-A fusion · CPC title

• C07K1/22 Primary

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• C07K14/31

  from Staphylococcus (G) · CPC title

• C07K14/00

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title